Acute Myeloblastic Leukemia clinical trials

Explore recruiting acute myeloblastic leukemia clinical trials.

Recruiting acute myeloblastic leukemia studies right now

Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Acute Myeloblastic Leukemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Single-centre Phase I/II study with dose escalation of tocilizumab in combination with venetoclax and azacitidine chemotherapy in patients with Acute Myeloid Leukaemia (AML): TOCIVENA

France

Human Pharmacology (Phase I)- Other EU CTIS Study details

Multicentric Phase 1 Study With Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine) or CPX-351 in Patients of 60 years old or more With adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)

France

Human Pharmacology (Phase I)- Other EU CTIS Study details

Monocentric phase 1 dose-escalation study of siltuximab in combination with idarubicin and cytarabine chemotherapy in patients with poor prognosis acute myelogenous leukemia (AML): SILTUXILAM

France

Human Pharmacology (Phase I)- Other EU CTIS Study details

Acute Myeloblastic Leukemia trials by city

Acute Myeloblastic Leukemia clinical trials

Recruiting acute myeloblastic leukemia studies right now

Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor

Novel Approaches to Target MECOM/EVI1 in AML

Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study

Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE

Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients

Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation

A Study of Rebecsinib for Patients With Relapsed/Refractory Secondary Acute Myeloid Leukemia or High Risk Myelofibrosis

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

UCMSC-Exo for Chemotherapy-induced Myelosuppression in Acute Myeloid Leukemia

Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis

Also recruiting in Europe

Single-centre Phase I/II study with dose escalation of tocilizumab in combination with venetoclax and azacitidine chemotherapy in patients with Acute Myeloid Leukaemia (AML): TOCIVENA

Multicentric Phase 1 Study With Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine) or CPX-351 in Patients of 60 years old or more With adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)

Monocentric phase 1 dose-escalation study of siltuximab in combination with idarubicin and cytarabine chemotherapy in patients with poor prognosis acute myelogenous leukemia (AML): SILTUXILAM

Acute Myeloblastic Leukemia trials by city

Other conditions